ENGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ENGN is not a good buy right now for a Beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has suffered a major fundamental setback after disappointing LEGEND trial results, and analysts have broadly cut ratings and price targets sharply. With no buy signal from Intellectica Proprietary Trading Signals, bearish moving averages, and weak sentiment from both news and analysts, the better call is to avoid buying now.
Current price is 1.72, just below the prior close of 1.78, with the stock still deeply damaged after the recent collapse. MACD histogram is positive and expanding, which suggests a short-term stabilization bounce, but the broader trend remains bearish because SMA_200 > SMA_20 > SMA_5. RSI_6 at 34.806 is neutral-to-weak, not signaling a strong reversal. Price is sitting near the pivot at 1.669, with resistance at 1.791 and 1.867 and support at 1.547 and 1.471. The technical picture is weak overall, and the one-day pattern forecast also leans negative.
["MACD histogram is positive and expanding, indicating short-term momentum may be improving.", "Some analysts still see a possible approval path for detalimogene despite weaker data.", "Option open interest put-call ratio below 1 suggests not all positioning is aggressively bearish.", "The stock is now near a low price level, which could attract speculative interest."]
["Disappointing interim LEGEND trial results showing only 25% 12-month duration of response.", "Stock collapsed about 80% after the trial update, indicating severe loss of market confidence.", "Pomerantz LLP is investigating securities fraud claims and urging investors to join a class action.", "Multiple analysts downgraded the stock and slashed price targets sharply.", "Bearish moving average structure remains intact.", "Historical pattern data suggests a negative near-term probability profile."]
No usable financial snapshot was provided, so there is no latest-quarter revenue or earnings trend to assess. For this company, the investment case is currently being driven more by clinical data and regulatory progress than by operating financial performance.
The analyst trend is sharply negative. Recent actions include UBS cutting its target to $2 and keeping Neutral, Oppenheimer downgrading to Perform, Leerink downgrading to Market Perform, Piper Sandler moving to Neutral, Guggenheim downgrading to Neutral, Raymond James cutting from Strong Buy to Outperform with a target reduced to $4, Citizens to Market Perform, Wells Fargo to Equal Weight, and Morgan Stanley to Equal Weight. The Wall Street view is now mostly cautious to bearish: pros still see a remaining approval possibility and some differentiation advantages, but the cons dominate, centered on disappointing efficacy, weaker durability, and worsening competitiveness. The overall analyst message is that ENGN has become a 'show-me' story.
